Orphan designation: infliximab Treatment of Kawasaki disease, 20/05/2026 Positive
Submitted by Anonymous (not verified) on 17 July 2026 - 11:25
Orphan designation: infliximab Treatment of Kawasaki disease, 20/05/2026 Positive
Orphan designation: allogeneic human induced pluripotent stem cell-derived photoreceptor precursor cells Treatment of non-syndromic inherited retinal dystrophies of the rod-dominant phenotype, 20/05/2026 Positive
Submitted by Anonymous (not verified) on 17 July 2026 - 11:21
Orphan designation: allogeneic human induced pluripotent stem cell-derived photoreceptor precursor cells Treatment of non-syndromic inherited retinal dystrophies of the rod-dominant phenotype, 20/05/2026 Positive
Orphan designation: allogeneic human Wharton's jelly-derived mesenchymal stem cells Treatment of Charcot-Marie-Tooth disease, 20/05/2026 Positive
Submitted by Anonymous (not verified) on 17 July 2026 - 11:19
Orphan designation: allogeneic human Wharton's jelly-derived mesenchymal stem cells Treatment of Charcot-Marie-Tooth disease, 20/05/2026 Positive
Orphan designation: peptide-oligonucleotide conjugate against CNOT3 mRNA Treatment of inherited retinal dystrophies due to mutation in the PRPF31 gene, 20/05/2026 Positive
Submitted by Anonymous (not verified) on 17 July 2026 - 11:04
Orphan designation: peptide-oligonucleotide conjugate against CNOT3 mRNA Treatment of inherited retinal dystrophies due to mutation in the PRPF31 gene, 20/05/2026 Positive
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 14-16 July 2026
Submitted by Anonymous (not verified) on 17 July 2026 - 11:00
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 14-16 July 2026
Orphan designation: allogeneic peripheral blood mononuclear cells incubated in vitro with mitomycin C Treatment of in solid organ transplantation, 20/05/2026 Positive
Submitted by Anonymous (not verified) on 17 July 2026 - 10:55
Orphan designation: allogeneic peripheral blood mononuclear cells incubated in vitro with mitomycin C Treatment of in solid organ transplantation, 20/05/2026 Positive
Clinical Trial Information System (CTIS) - Sponsor handbook
Submitted by Anonymous (not verified) on 17 July 2026 - 9:10
Clinical Trial Information System (CTIS) - Sponsor handbook
Highlights - European Medicines Agency (EMA) / European Chemicals Agency (ECHA) joint meeting with industry stakeholders
Submitted by Anonymous (not verified) on 17 July 2026 - 9:01
Highlights - European Medicines Agency (EMA) / European Chemicals Agency (ECHA) joint meeting with industry stakeholders
Horizon scanning: Identifying emerging trends
Submitted by Anonymous (not verified) on 17 July 2026 - 9:00
Horizon scanning: Identifying emerging trends
Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - July 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 17 July 2026, 10:00 (CEST) to 17 July 2026, 11:30 (CEST)
Submitted by Anonymous (not verified) on 17 July 2026 - 7:35
Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - July 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 17 July 2026, 10:00 (CEST) to 17 July 2026, 11:30 (CEST)